Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease

Chhabra, Saurabh; Jerkins, James; Conto, John; Zellner, Katie R.; Shah, Nirav N.; Hari, Parameswaran; Hamadani, Mehdi

doi:10.1080/10428194.2019.1695049

Cited by 19 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, FDA-approved drugs that potentially target hub genes were predicted, and six antagonists/inhibitors were found: lifitegrast, siltuximab, belatacept, abatacept, phenprocoumon, and maraviroc. Lifitegrast targets ITGB2 and is applied in the treatment of ocular chronic graft-versus-host disease [93] . Siltuximab is a human–mouse chimeric monoclonal antibody that targets human IL-6 and inhibits the IL-6 pro-inflammatory pathway in pig-to-baboon organ xenotransplantation models [94] .…”

Section: Discussionmentioning

confidence: 99%

Screening and identification of key regulatory connections and immune cell infiltration characteristics for lung transplant rejection using mucosal biopsies

Xiu

Liu

Tang

2020

International Immunopharmacology

View full text Add to dashboard Cite

Highlights Identifying hub genes for lung allograft rejection. Constructing a miRNA-TF-mRNA regulatory network in lung allograft rejection. Revealing dysregulation of immune cells during lung allograft rejection. Revealing potential relationships between hub gene expression and immune cell infiltration level. Predicting potential drugs for the treatment of lung allograft rejection.

show abstract

Section: Discussionmentioning

confidence: 99%

Screening and identification of key regulatory connections and immune cell infiltration characteristics for lung transplant rejection using mucosal biopsies

Xiu

Liu

Tang

2020

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

“…[128][129][130] It has been shown in multiple clinical trials to be effective for the treatment of DED [128][129][130] including severe cases such as those with graft versus host disease. 131 In such studies it has been shown to significantly improve inferior corneal fluorescein staining scores and eye dryness scores, with limited adverse effects such as ocular irritation and dysgeusia. [128][129][130] There are as yet no published studies of its usage after cataract surgery in the prevention of DED, but Hovanesian et al 132 have reported improvements in higher-order aberrations, accuracy of pre-operative biometry, as well DED symptom scores, TBUTs and corneal fluorescein staining in patients using lifitegrast.…”

Section: Other Treatment Interventionsmentioning

confidence: 99%

Cataract surgery and dry eye disease: A review

Naderi

Gormley

O’Brart

2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

Aim To review published literature concerning cataract surgery and dry eye disease (DED). Methods A search was undertaken using the following: PubMed (all years), Web of Science (all years), Ovid MEDLINE(R) (1946 to 12 December 2019), Ovid MEDLINE(R) Daily Update 10 December 2019, MEDLINE and MEDLINE non-indexed items, Embase (1974–2019, week 49), Ovid MEDLINE (R) and Epub Ahead of Print, In-Process and Other Non-Indexed Citations and Daily (1946 to 12 December 2019), CENTRAL (including Cochrane Eyes and Vision Trials Register; Cochrane Library: Issue 12 of 12 December 2019), metaRegister of Controlled Trials (mRCT) ( www.controlled-trials.com ), ClinicalTrials.gov ( www.clinicaltrial.gov ) and WHO International Clinical Trials Registry Platform ( www.who.int/ictrp/search/en ). Search terms included ‘cataract surgery’, ‘phacoemulsification’ and ‘cataract extraction’, combined with ‘dry eyes’ and ‘ocular surface’. Relevant in-article references not returned in our searches were also considered. Results Publications identified included systematic reviews, meta-analysis, randomized controlled trials, cohort studies, case series and laboratory-based studies. Published data highlighting the burden of DED both prior and following cataract surgery were reviewed as well as studies highlighting the effects of cataract surgery on the ocular surface, intra-operative measures to reduce deleterious effects on the ocular surface and current evidence on the management options of post-operative DED. Conclusions DED is common and can be exacerbated by cataract surgery. Ophthalmologists need to assess for pre-existing DED and instigate treatment before surgery; be aware of reduced accuracy of measurements for surgical planning in the presence of DED; limit intra-operative surgical factors damaging to the ocular surface; and consider management to reduce DED post-operatively.

show abstract

“…[129][130][131][132] While there have been no large scale prospective studies, Chhabra and others showed improved NIH severity symptoms scores in oGVHD with the use of 5% lifitegrast BID. 133 In this small retrospective case study series, approximately half (46%) of the patients had an improvement and none of the other patients had an increase in symptoms while on the lifitegrast. The majority of the patients (87%) had been on and failed artificial tears and topical cyclosporine.…”

Section: Management Of Chronic Ogvhdmentioning

confidence: 71%

Chronic Ocular Graft Versus Host Disease: An Update and Review

Groth

Conto

Pasquini

2020

JDED

View full text Add to dashboard Cite

An updated comprehensive literature review was completed of chronic ocular graft versus host disease (oGVHD) to identify current and future considerations as to the causes, diagnosis, and treatment of this complication after allogenic hematopoietic cell transplantation (HCT). Graft-versus-host disease involves multiple organ systems, including the eye, and is a leading cause of mortality and morbidity in these patients. This review consisted a comprehensive search of the PubMed, ClinicalTrials.gov and NIH.gov databases. oGVHD is a debilitating and potentially sight threatening condition. Commonly involved ocular structures include the cornea, conjunctiva, meibomian glands, eyelids, lacrimal gland and tear film. Identifying and treating the ocular complications at the early stages may improve final outcomes and quality of life in these patients. Aggressive lubrication, preservation of tear film and inflammation control, including minimizing surface scarring, are treatment goals. Co-management with HCT and other pertinent health care providers is critical for early diagnosis and to initiate prompt therapy to minimize the ocular damage. Stepped therapy, including the use of emerging systemic treatments can be useful in the management of oGVHD with stable visual function, quality of life and complication management as goals of treatment.

show abstract

Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease

Cited by 19 publications

References 34 publications

Screening and identification of key regulatory connections and immune cell infiltration characteristics for lung transplant rejection using mucosal biopsies

Screening and identification of key regulatory connections and immune cell infiltration characteristics for lung transplant rejection using mucosal biopsies

Cataract surgery and dry eye disease: A review

Chronic Ocular Graft Versus Host Disease: An Update and Review

Contact Info

Product

Resources

About